Patents by Inventor Seshidhar Reddy Police

Seshidhar Reddy Police has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210047656
    Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.
    Type: Application
    Filed: December 23, 2019
    Publication date: February 18, 2021
    Inventors: Vivian CHOI, Chad Eric BIGELOW, Thaddeus Peter DRYJA, Seshidhar Reddy POLICE
  • Publication number: 20210047649
    Abstract: The present disclosure provides materials and methods for treating a patient with Duchenne Muscular Dystrophy (DMD), e.g., through ex vivo and in vivo methods of genome editing. The present disclosure also relates to methods and compositions for use of self-inactivating/self-targeting CRISPR/Cas or CRISPR/Cpf1 systems to genetically modify cells, e.g., to modulate the expression, function, and/or activity of the dystrophin gene.
    Type: Application
    Filed: May 8, 2020
    Publication date: February 18, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Robert NG, Seshidhar Reddy POLICE, Yanfei YANG
  • Publication number: 20210032622
    Abstract: The invention relates to self-inactivating/self-targeting CRISPR/Cas or CRISPR/Cpf1 systems. The invention also relates to genetically modified cells related to the same. The invention also relates to methods of controlling Cas9 expression in a cell related to the same. The invention also relates to methods of genetically modifying a cell related to the same. The invention also relates to nucleic acids for use in a self-inactivating CRISPR/Cas or CRISPR/Cpf1 system. The invention also relates to pharmaceutical compositions related to the same.
    Type: Application
    Filed: November 9, 2018
    Publication date: February 4, 2021
    Inventors: Seshidhar Reddy POLICE, Song CHOU, Thomas James CRADICK, Robert NG
  • Patent number: 10550404
    Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: February 4, 2020
    Assignee: NOVARTIS AG
    Inventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
  • Publication number: 20190010495
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: December 26, 2016
    Publication date: January 10, 2019
    Applicants: NOVARTIS AG, INTELLIA THERAPEUTICS, INC.
    Inventors: Anthony Edward BOITANO, Michael COOKE, Lloyd B. KLICKSTEIN, Reynald LESCARBEAU, Craig Stephen MICKANIN, Kabungo MULUMBA, Seshidhar Reddy POLICE, Jennifer SNEAD, Susan C. STEVENSON, Morag STEWART, Yi YANG
  • Publication number: 20180080046
    Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.
    Type: Application
    Filed: September 22, 2017
    Publication date: March 22, 2018
    Applicant: Novartis AG
    Inventors: Vivian CHOI, Chad Eric BIGELOW, Thaddeus Peter DRYJA, Seshidhar Reddy POLICE
  • Patent number: 9803217
    Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: October 31, 2017
    Assignee: NOVARTIS AG
    Inventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
  • Publication number: 20160097061
    Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.
    Type: Application
    Filed: October 13, 2015
    Publication date: April 7, 2016
    Applicant: NOVARTIS AG
    Inventors: Vivian CHOI, Chad Eric BIGELOW, Thaddeus Peter DRYJA, Seshidhar Reddy POLICE
  • Patent number: 9163259
    Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: October 20, 2015
    Assignee: Novartis AG
    Inventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
  • Publication number: 20140348798
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Application
    Filed: March 7, 2014
    Publication date: November 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Paul L. HALLENBECK, Seshidhar Reddy POLICE, Laura M. HALES, Carl M. HAY, Shanthi GANESH, Ling XU, Jingping YANG, Cheng CHENG
  • Patent number: 8753622
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: June 17, 2014
    Assignee: Novartis AG
    Inventors: Paul Hallenbeck, Seshidhar Reddy Police, Laura M. Hales, Carl Hay, Shanthi Ganesh, Ling Xu, Jingping Yang, Cheng Cheng
  • Publication number: 20140017201
    Abstract: The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy.
    Type: Application
    Filed: April 30, 2013
    Publication date: January 16, 2014
    Applicant: NOVARTIS AG
    Inventors: Vivian Choi, Chad Eric Bigelow, Thaddeus Peter Dryja, Seshidhar Reddy Police
  • Patent number: 8039606
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: October 18, 2011
    Assignee: Novartis AG
    Inventors: Paul Hallenbeck, Seshidhar Reddy Police, Laura M. Hales, Carl Hay, Shanthi Ganesh, Ling Xu, Jingping Yang, Cheng Cheng
  • Publication number: 20100129325
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Application
    Filed: October 9, 2009
    Publication date: May 27, 2010
    Applicant: NOVARTIS AG
    Inventors: Paul L. HALLENBECK, Seshidhar Reddy POLICE, Laura M. HALES, Carl M. HAY, Shanthi GANESH, Ling XU, Jingping YANG, Cheng CHENG
  • Publication number: 20030104625
    Abstract: The present invention relates to oncolytic adenoviral vectors and their use in methods of gene therapy. Provided is a recombinant viral vector comprising an adenoviral nucleic acid backbone, wherein said nucleic acid backbone comprises in sequential order: A left ITR, a termination signal sequence, an E2F responsive promoter which is operably linked to a gene essential for replication of the recombinant viral vector, an adenoviral packaging signal, and a right ITR.
    Type: Application
    Filed: February 22, 2002
    Publication date: June 5, 2003
    Inventors: Cheng Cheng, Lori Clarke, Sheila Connelly, David Leonard Ennist, Suzanne Forry-Schaudies, Mario Gorziglia, Paul L. Hallenbeck, Carl M. Hay, John Leonard Jakubczak, Michael Kaleko, Sandrina Phipps, Seshidhar Reddy Police, Patricia Clare Ryan, David A. Stewart, Yuefeng Xie